GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Intrinsic Value: Projected FCF

Shanghai HeartCare Medical Technology (HKSE:06609) Intrinsic Value: Projected FCF : HK$0.00 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-07), Shanghai HeartCare Medical Technology's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Shanghai HeartCare Medical Technology is HK$16.88. Therefore, Shanghai HeartCare Medical Technology's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Shanghai HeartCare Medical Technology's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:06609's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.67
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Shanghai HeartCare Medical Technology Intrinsic Value: Projected FCF Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Intrinsic Value: Projected FCF Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Shanghai HeartCare Medical Technology's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's Price-to-Projected-FCF falls into.



Shanghai HeartCare Medical Technology Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Shanghai HeartCare Medical Technology  (HKSE:06609) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Shanghai HeartCare Medical Technology's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=16.88/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines